Eloxx Pharmaceuticals, Inc. (ELOX) News
Filter ELOX News Items
ELOX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ELOX News Highlights
- For ELOX, its 30 day story count is now at 3.
- Over the past 21 days, the trend for ELOX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about ELOX are ADM, DRUG and RARE.
Latest ELOX News From Around the Web
Below are the latest news stories about ELOXX PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ELOX as an investment opportunity.
Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of ProteinuriaPodocyte Exact Morphology Procedure Results Podocyte Exact Morphology Procedure Results ELX-02 treatment improved podocyte foot process effacement in all three patients by an average of 60% based on a blinded kidney biopsy analysis by NIPOKA GmbH Biopsy results support clinical benefit in all three patients as improvement of kidney morphology is consistent with reduction or stabilization of proteinuria during or up to 2 months post completion of dosing Renowned key opinion leaders recommend cont |
Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesWATERTOWN, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 380,590 of its shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $5.255 per share (or common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market |
Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport SyndromeHighly regarded renal pathologist and transmission electron microscopy (TEM) expert independently confirms previously reported qualitative assessment by Mayo Clinic of TEM biopsy scans All three patients treated with ELX-02 showed a visual improvement in podocyte foot process effacement post-treatment in kidney biopsies demonstrating the disease modifying effect of ELX-02 Podocyte foot process effacement is a hallmark of Alport syndrome Eloxx intends to gain alignment with U.S. Food and Drug Adm |
Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013Investigational New Drug (IND) application submitted to U.S. Food and Drug Administration (FDA) for ELX-02 for the treatment of Alport syndrome with nonsense mutations Rebound in average UPCR 3-months post treatment provides further evidence that proteinuria remission in one out of three patients was drug related All 3 Alport patients (100% response rate) treated with ELX-02 had biopsy confirmed disease regression, suggesting clinical benefit likely with longer treatment duration Significant str |
Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport SyndromeAll three patients (100% response rate) treated with ELX-02 showed an improvement in podocyte foot process effacement post-treatment in kidney biopsies assessed by electron microscopy demonstrating the disease modifying effect of ELX-02 Podocyte foot process effacement is a hallmark of Alport syndrome Together with previously announced rapid and sustained proteinuria remission in one patient in Phase 2 clinical study, these biopsy results strongly support decision to advance ELX-02 into a pivota |
Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing RequirementWATERTOWN, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it received notice from the Nasdaq Listing Qualifications Panel (the “Hearings Panel”) of The Nasdaq Stock Market LLC (“Nasdaq”) that it has determined to extend the exception granted on June 2, 2023 to Eloxx Pharmaceuticals, Inc. (the “Company”) to regain compliance with Listing Rule 5550(b)(2), which require |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayIt's time to start off Wednesday with an overview of all the biggest pre-market stock movers worth watching this morning! |
Dow Up 138 Points As Nasdaq FlatlinesInvestors are largely expecting the Federal Reserve to hike interest rates by 25 basis points later this month, but the jury is still out as far as its September decision is concerned. |
Eloxx Pharmaceuticals Announces Publication Demonstrating the Power of its TURBO-ZM™ Platform to Target the Human Ribosome for Therapeutic BenefitPublication titled “A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer” published in Cancer Research Communications Results suggest that MYC overexpressing cancers can be targeted by exploiting ribosome heterogeneity in cancer; preclinical data demonstrated activity of ZKN-157 against subtypes of colorectal cancer Research potentially opens large opportunities to selectively target MYC-driven cancers with |
Eloxx Pharmaceuticals Key Opinion Leader Event Highlights Significant Unmet Need in Treatment of Alport Syndrome Patients with Nonsense Mutations and Additional Positive Results from Phase 2 Clinical Study Evaluating ELX-02Alport syndrome is a rare progressive hereditary glomerular kidney disease caused by variants in COL4A and patients have significant unmet medical needs, with no disease modifying treatments currently available Eloxx announced additional results from its Phase 2 ELX-02 trial showing the patient that achieved a remission rebounded one month after withdrawing treatment, providing additional evidence of drug activity Eloxx intends to advance into a pivotal trial of ELX-02 for the treatment of Alpor |